# Ares Commercial Real Estate Corp: financial statements, quarterly

ACRE · NYSE · CIK 1529377 · [Real estate](/sectors/real-estate.md)

Pages: [Overview](/companies/acre.md) · [Financials](/companies/acre/financials.md) · [Filings](/companies/acre/filings.md) · [Insiders](/companies/acre/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/acre/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [23.9](/filings/0001628280-24-045922.md) | [17.6 d](/filings/0001628280-26-006635.md) | [18.7](/filings/0001628280-25-022833.md) | [16.8](/filings/0001628280-25-037529.md) | [16.7](/filings/0001628280-25-050392.md) | [17.5 d](/filings/0001628280-26-006635.md) | [14.9](/filings/0001628280-26-031613.md) | [12.6](/filings/0001628280-26-052072.md) | [14.1](/filings/0001628280-25-050392.md) | [13.2 d](/filings/0001628280-26-006635.md) | [13.5](/filings/0001628280-26-031613.md) | [14.4](/filings/0001628280-26-052072.md) |
| Income tax | $m | [(0.0)](/filings/0001628280-24-045922.md) | [(0.1) d](/filings/0001628280-26-006635.md) | [0.0](/filings/0001628280-25-022833.md) | [0.0](/filings/0001628280-25-037529.md) | [(0.0)](/filings/0001628280-25-050392.md) | [(0.0) d](/filings/0001628280-26-006635.md) | [0.3](/filings/0001628280-26-031613.md) | [0.0](/filings/0001628280-26-052072.md) | [(0.0)](/filings/0001628280-25-050392.md) | [0.0 d](/filings/0001628280-26-006635.md) | [0.0](/filings/0001628280-26-031613.md) | [0.1](/filings/0001628280-26-052072.md) |
| Net income | $m | [9.2](/filings/0001628280-24-045922.md) | [(39.4)](/filings/0001628280-24-045922.md) | [(12.3)](/filings/0001628280-25-050392.md) | [(6.1)](/filings/0001628280-25-050392.md) | [(5.9)](/filings/0001628280-25-050392.md) | [(10.7)](/filings/0001628280-25-050392.md) | [9.3](/filings/0001628280-26-052072.md) | [(11.0)](/filings/0001628280-26-052072.md) | [4.7](/filings/0001628280-26-052072.md) | [(3.9)](/filings/0001628280-26-052072.md) | [(9.6)](/filings/0001628280-26-052072.md) | [4.4](/filings/0001628280-26-052072.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue: us-gaap:Revenues
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: not reported
- Basic EPS: not reported

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [61.0](/filings/0001628280-24-045922.md) | [110](/filings/0001628280-26-006635.md) | [99.5](/filings/0001628280-25-022833.md) | [70.6](/filings/0001628280-25-037529.md) | [68.9](/filings/0001628280-25-050392.md) | [63.8](/filings/0001628280-26-006635.md) | [125](/filings/0001628280-26-031613.md) | [90.0](/filings/0001628280-26-052072.md) | [84.9](/filings/0001628280-25-050392.md) | [29.3](/filings/0001628280-26-052072.md) | [86.2](/filings/0001628280-26-031613.md) | [17.6](/filings/0001628280-26-052072.md) |
| Total assets | $m | [2,363](/filings/0001628280-23-036540.md) | [2,280](/filings/0001628280-25-005002.md) | [2,111](/filings/0001628280-24-021911.md) | [2,070](/filings/0001628280-24-034916.md) | [1,941](/filings/0001628280-24-045922.md) | [1,751](/filings/0001628280-26-006635.md) | [1,520](/filings/0001628280-25-022833.md) | [1,439](/filings/0001628280-25-037529.md) | [1,392](/filings/0001628280-25-050392.md) | [1,618](/filings/0001628280-26-052072.md) | [1,836](/filings/0001628280-26-031613.md) | [1,817](/filings/0001628280-26-052072.md) |
| Total liabilities | $m | [1,680](/filings/0001628280-23-036540.md) | [1,654](/filings/0001628280-25-005002.md) | [1,510](/filings/0001628280-24-021911.md) | [1,487](/filings/0001628280-24-034916.md) | [1,377](/filings/0001628280-24-045922.md) | [1,211](/filings/0001628280-26-006635.md) | [977](/filings/0001628280-25-022833.md) | [915](/filings/0001628280-25-037529.md) | [871](/filings/0001628280-25-050392.md) | [1,109](/filings/0001628280-26-052072.md) | [1,344](/filings/0001628280-26-031613.md) | [1,328](/filings/0001628280-26-052072.md) |
| Long-term debt | $m | not reported | [895](/filings/0001628280-24-006105.md) | not reported | not reported | not reported | [718](/filings/0001628280-25-005002.md) | not reported | not reported | not reported | [948](/filings/0001628280-26-006635.md) | not reported | not reported |
| Shareholders' equity | $m | [683](/filings/0001628280-23-036540.md) | [626](/filings/0001628280-26-006635.md) | [601](/filings/0001628280-25-050392.md) | [582](/filings/0001628280-25-050392.md) | [564](/filings/0001628280-25-050392.md) | [540](/filings/0001628280-26-052072.md) | [542](/filings/0001628280-26-052072.md) | [524](/filings/0001628280-26-052072.md) | [521](/filings/0001628280-26-052072.md) | [510](/filings/0001628280-26-052072.md) | [492](/filings/0001628280-26-052072.md) | [489](/filings/0001628280-26-052072.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [13.5 d](/filings/0001628280-24-045922.md) | [10.1 d](/filings/0001628280-26-006635.md) | [11.4](/filings/0001628280-25-022833.md) | [8.7 d](/filings/0001628280-25-037529.md) | [8.4 d](/filings/0001628280-25-050392.md) | [7.1 d](/filings/0001628280-26-006635.md) | [8.0](/filings/0001628280-26-031613.md) | [4.9 d](/filings/0001628280-26-052072.md) | [3.8 d](/filings/0001628280-25-050392.md) | [4.6 d](/filings/0001628280-26-006635.md) | [(56.6)](/filings/0001628280-26-031613.md) | [63.5 d](/filings/0001628280-26-052072.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Dividends paid | $m | [19.2 d](/filings/0001628280-24-045922.md) | [18.1 d](/filings/0001628280-26-006635.md) | [18.2](/filings/0001628280-25-022833.md) | [13.8 d](/filings/0001628280-25-037529.md) | [13.8 d](/filings/0001628280-25-050392.md) | [13.8 d](/filings/0001628280-26-006635.md) | [13.9](/filings/0001628280-26-031613.md) | [8.4 d](/filings/0001628280-26-052072.md) | [8.4 d](/filings/0001628280-25-050392.md) | [8.4 d](/filings/0001628280-26-006635.md) | [8.4](/filings/0001628280-26-031613.md) | [8.4 d](/filings/0001628280-26-052072.md) |
| Share repurchases | $m | [0.0 d](/filings/0001628280-24-045922.md) | [0.0 d](/filings/0001628280-26-006635.md) | not reported | not reported | [0.0 d](/filings/0001628280-24-045922.md) | [0.0 d](/filings/0001628280-26-006635.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [54.8](/filings/0001628280-23-036540.md) | [54.6](/filings/0001628280-24-021911.md) | [54.3](/filings/0001628280-24-034916.md) | [54.8](/filings/0001628280-24-045922.md) | [54.4](/filings/0001628280-25-022833.md) | [54.4](/filings/0001628280-25-037529.md) | [54.5](/filings/0001628280-25-050392.md) | [55.7](/filings/0001628280-26-031613.md) | [54.9](/filings/0001628280-26-052072.md) | [55.8](/filings/0001628280-25-050392.md) | [55.3](/filings/0001628280-26-031613.md) | [56.4](/filings/0001628280-26-052072.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 55,481,113 at 2026-07-30, from the cover of the [10-Q filed 2026-08-04](/filings/0001628280-26-052072.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.